BICO Group Future Growth

Future criteria checks 4/6

BICO Group is forecast to grow earnings and revenue by 130.2% and 10.9% per annum respectively. EPS is expected to grow by 130.1% per annum. Return on equity is forecast to be 2.3% in 3 years.

Key information

130.2%

Earnings growth rate

130.1%

EPS growth rate

Life Sciences earnings growth	18.8%
Revenue growth rate	10.9%
Future return on equity	2.3%
Analyst coverage	Low
Last updated	15 Nov 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

OTCPK:CLLK.F - Analysts future estimates and past financials data (SEK Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	2,925	100	N/A	N/A	1
12/31/2025	2,618	-27	-38	146	2
12/31/2024	2,299	-177	-420	-142	2
9/30/2024	2,331	-1,704	48	139	N/A
6/30/2024	2,423	-1,498	-35	98	N/A
3/31/2024	2,426	-1,649	-98	101	N/A
12/31/2023	2,405	-1,697	-113	178	N/A
9/30/2023	2,213	-497	-435	-53	N/A
6/30/2023	2,256	-390	-527	-72	N/A
3/31/2023	2,297	-117	-643	-140	N/A
12/31/2022	2,327	-85	-799	-269	N/A
9/30/2022	2,278	41	-817	-313	N/A
6/30/2022	1,995	-130	-872	-457	N/A
3/31/2022	1,743	-224	-816	-462	N/A
12/31/2021	1,378	-228	-676	-409	N/A
9/30/2021	993	-188	-529	-321	N/A
6/30/2021	744	-96	-328	-150	N/A
3/31/2021	460	-50	-156	-34	N/A
12/31/2020	369	-36	-160	-59	N/A
8/31/2020	236	-62	-154	-72	N/A
5/31/2020	213	-49	-146	-70	N/A
2/29/2020	197	-24	-115	-53	N/A
11/30/2019	173	-5	-73	-31	N/A
8/31/2019	135	1	-52	-16	N/A
5/31/2019	118	3	-59	-16	N/A
2/28/2019	97	4	-38	-2	N/A
11/30/2018	76	2	-34	-12	N/A
8/31/2018	61	1	N/A	-12	N/A
5/31/2018	45	1	N/A	-6	N/A
2/28/2018	34	-2	N/A	-7	N/A
11/30/2017	27	-2	N/A	-8	N/A
8/31/2017	20	-1	N/A	-1	N/A
8/31/2016	6	-1	N/A	-2	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CLLK.F is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: CLLK.F is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: CLLK.F is expected to become profitable in the next 3 years.

Revenue vs Market: CLLK.F's revenue (10.9% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: CLLK.F's revenue (10.9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: CLLK.F's Return on Equity is forecast to be low in 3 years time (2.3%).

BICO Group Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Recent updates

Lab14 GmbH acquired Nanoscribe GmbH from BICO Group AB (publ) (OM:BICO) for €26 million.

Lab14 GmbH acquired Nanoscribe GmbH from BICO Group AB (publ) (OM:BICO) for €26 million.

BICO Group AB (publ) to Report Fiscal Year 2024 Final Results on Mar 20, 2025

BICO Group AB (publ), Annual General Meeting, May 08, 2025

BICO Group AB Announces Management Changes

BICO Group AB (publ) Elects Alexandra Gatzemeyer as Member of the Board of Directors

BICO Group AB (publ) Announces the Appointment of Anders Fogelberg as Chief Commercial Officer, Effective June 13, 2024

BICO Group AB (publ) Announces Gerry Mackay and Erik Gatenholm Decline Re-Election of the Board of Directors

BICO Group AB (publ) to Report Fiscal Year 2024 Results on Feb 19, 2025

BICO Group AB (publ) to Report Q3, 2024 Results on Nov 13, 2024

BICO Group AB (publ) Appoints Catharina Nordlund as Global Head of HR

BICO Group AB (publ) to Report Fiscal Year 2023 Results on Mar 15, 2024

BICO Group AB (publ) Announces Chief Executive Officer Changes

Beos Light Industrial Germany 1 Fund, a fund managed by BEOS AG agreed to acquire property on Wagner-Régeny-Straße 15 from BICO Group AB (publ) (OM:BICO) for €21 million.

BICO Group AB (publ) Elects Gerry Mackay to Its Board of Directors

BICO Group AB (publ) to Report Fiscal Year 2023 Results on Feb 20, 2024

BICO Group AB Appoints Marius Balger as Chief Operating Officer, Effective March 1, 2023

BICO Group AB Announces the Appointment of Jacob Thordenberg as Group CFO

BICO Group AB (publ) to Report Q1, 2023 Results on May 04, 2023

BICO Group AB (publ) to Report Q2, 2023 Results on Jul 20, 2023

BICO Group Announces Appointment of Nomination Committee 2023

BICO Group AB (publ) to Report Fiscal Year 2023 Results on Feb 22, 2023

BICO Group Adds Åsa Hillsten as SVP and Head of IR

BICO Group AB (publ) (OM : BICO) acquired Allegro 3D for $11 million.

BICO (publ) Appoints Mikael Engblom as Interim CFO

BICO Group AB (Publ) Announces Board Appointments

BICO Reaches Beneficial and Sustainable Solution with Organovo

DISPENDIX, A BICO Company, Announces That the I.DOT HT Non-contact Dispenser and the L.DROP Liquid Handler will be introduced at SLAS 2022

BICO Group AB Announces Statement Regarding Counterclaims in Patent Lawsuit by Organovo Against Cellink

BICO Group AB (publ) (OM:BICO) agreed to acquire Biosero Llc.

BICO Group AB (publ) (OM:BICO) acquired all outstanding shares in Advanced BioMatrix, Inc. for $18 million.

CELLINK Receives Patent for Robotic Systems for Personalized and Automated Aesthetic Medical Procedures

Cellink AB (publ) (OM:CLNK B) completed the acquisition of Discover Echo Inc.

Cellink AB (publ) (OM:CLNK B) completed the acquisition of Nanoscribe GmbH for approximately €37 million.

Cellink AB (publ) (OM:CLNK B) entered into an agreement to acquire Nanoscribe GmbH for €34 million.

Cellink AB (publ) (OM:CLNK B) entered into an agreement to acquire MatTek Corporation for $68 million.

Cellink AB (publ) (OM:CLNK B) completed the acquisition of Ginolis Ltd from Verso Fund II of Verso Capital Oy, Finnvera plc and Innovestor Ventures for €65.7 million.

Cellink AB (publ) to Report Fiscal Year 2021 Results on Mar 16, 2022

Cellink AB (publ) (OM:CLNK B) entered into an agreement to acquire Ginolis Ltd for €70 million.

Cellink AB (publ) Announces Distribution Agreement Including New Products for Single-Cell RNA Sequencing and NGS Library Preparation

Cellink Announces Third Year Extension of Collaboration with A Global Biopharmaceutical Company for Drug Discovery

Cellink and Phasefocus Announces a Partnership to Bring Livecyte High Content Live Cell Imager to a Wider Audience

Cellink AB (publ) Elects Aristotelis Nastos as Member of the Board of Directors

CELLINK and Atelerix Team Up to Enable the Shipping At Room Temperature of Fragile 3D Bioprinted Constructs by the World's Bioprinting Community

CELLINK to Help Develop 3D Bioprinted Personalised Scaffolds for Tissue Regeneration of Ankle Joint S as Part of the Triankle Project

Cellink AB (publ) to Report Second Half, 2020 Results on Oct 22, 2020

Cellink AB (Publ) Announces Leaving Board of Directors for an Operational Role as Business Area Manager for the Bioprinting Business Unit

Cellink AB (publ) (OM:CLNK B) completed the acquisition of SCIENION AG from NRW.Bank Venture Fonds, L.P., managed by NRW.Bank, Investment Arm and other shareholders.

Cellink AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 945.99632 million.

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies